Clinical Pharmacokinetic Significance of the Renal Tubular Secretion of Digoxin
Tubular secretion appears to be a major route of the renal elimination of digoxin. Secretion of the drug by the tubules is modulated by renal blood flow, by a number of commonly coadministered drugs (e.g. quinidine, spironolactone, verapamil, amiodarone), and by age. The maximal transport capacity does not appear to be achieved with clinically relevant concentrations. The tubular transport of digoxin does not appear to be associated with the anionic or cationic transport systems, nor the Na+/K+-ATPase receptor.
Further studies are needed to elucidate the exact mechanisms involved in the transtubular movement of the glycoside.
KeywordsDigoxin Inulin Quinidine Spironolactone Renal Blood Flow
Unable to display preview. Download preview PDF.
- Aronson JK. An account of the foxglove and some of its medical uses, 1785–1985, Oxford Medical Publication, Oxford 1985Google Scholar
- Goldfrank LR. Toxicologic emergencies. Appleton-Century-Crofts, New York, 1986Google Scholar
- Koren G, Klein J, Ben Dayan R, MacLeod SM, Silverman M. Simultaneous inhibition of the renal and biliary transport of digoxin by quinidine. Clinical and Investigative Medicine, in press, 1987Google Scholar
- Koren G, Klein J, MacLeod SM, Silverman M. Digoxin handling by the renal tubular cell. Clinical and Investigative Medicine 9: A16, 1986aGoogle Scholar
- Koren G, Klein J, MacLeod SM, Silverman M. Digoxin handling by the renal tubular cell. Clinical Research 34: 867A, 1986bGoogle Scholar
- Koren G, MacLeod SM, Silverman M. Application of novel in vivo and in vitro methods to the study of renal digoxin handling. Abstract No. 1034, Proceedings of the III World Conference on Clinical Pharmacology and Therapeutics, Stockholm, 1986cGoogle Scholar
- Koren G, Soldin S, MacLeod SM. Interaction of digoxin with verapamil, indomethacin and other co-administered drugs: a comparative study in rat tissue. In MacLeod et al. (Eds). Proceedings of the International Congress of Developmental Pharmacology, Toronto, October 1982, pp. 417–420, Allan R. Liss Inc, New York, 1983cGoogle Scholar
- Nier AS, Shand DG, Wilkinson GR. Altered hepatic blood flow and drug disposition. In Gibaldi and Prescott (Eds) Handbook of clinical pharmacokinetics, section I, pp. 77–96, ADIS Health Science Press, Syndey, 1983Google Scholar
- Ogilvie RI, Dorian P, Strauss M, Cardella C, David T. Digoxincyclosporine interaction: a new phenomenon. Abstract No. 1100, Proceedings of the III World Conference on Clinical Pharmacology & Therapeutics, Stockholm, 1986Google Scholar
- Pedersen KE. Digoxin interactions. Acta Medica Scandinavica (Supp. 697): 1–40, 1985Google Scholar
- Rameis H. Quinidine-digoxin interaction: are the pharmacokinetics of both drugs altered. International Journal of Clinical Pharmacology and Therapeutics Toxicology 23: 145–153, 1985Google Scholar
- Rennick B, Quabbenzann AJ. Renal tubular excretion of drugs: proximal tubule and metabolism. In Fisher & Cafruny (Eds). Renal pharmacology, p. 68, Appleton-Century-Crofts, New York, 1971Google Scholar
- Tallardia RJ. Most prescribed drugs 1985, WB Saunders Co., Philadelphia, 1985Google Scholar
- Wilson DM. Tests of renal function. In Frohnert (Ed.) Clinical Medicine, Vol. 7, Harpers Row, Philadelphia, 1985Google Scholar